Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | CSK | P41240 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702258 | 0.94 | LPL (0.52) | LPLLIPGCA2CA1F11 | |
| SCHEMBL18513319 | 0.84 | LPL (0.56) | LPLLIPGCA2CA1F11 | |
| SCHEMBL14478270 | 0.83 | TAAR1 (0.61) | LPLLIPGF11CSK | |
| SCHEMBL14478212 | 0.83 | TAAR1 (0.61) | LPLLIPGF11CSK | |
| SCHEMBL18244894 | 0.81 | PTGS1 (0.45) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL6778600 | 0.81 | LPL (0.57) | LPLLIPGCA2CA1F11 | |
| Hydrogen Peroxide SCHEMBL9581174 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL1131597 | 0.80 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL14510694 | 0.79 | CSK (0.51) | LPLLIPGCA2CA1F11 | |
| SCHEMBL22960687 | 0.79 | CXCR1 (0.42) | PTGS1PTGS2LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | claimed |
| US-12439813-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPRATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-08-26 | — | — | US | disclosed |
| WO-2025090793-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-115232090-B | 6-Substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2, 2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2024-11-19 | — | — | CN | disclosed |
| CN-118978550-A | Organic electroluminescent material and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-116354897-B | Substituted 1,2, 4-triazole, pyridine and pyrimidine derivatives and application thereof in medicines | 华东师范大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-118660875-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2024-09-17 | — | — | CN | disclosed |
| US-5861401-A | TREATMENT OF CONGESTIVE HEART FAILURE | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0752986-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995026957-A1 | N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1995-10-12 | — | — | WO | disclosed |
| EP-0640596-A1 | N-pyridazinyl-benzene (naphthalene-, biphenyl-) sulfonamide derivatives, their preparation and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12439813-B2 | Organic electroluminescent materials and devices | OCIAD2, DRD2, OPRD1 | LPL 1385/4885LIPG 1924/4885CA2 3302/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | LPL 141/4885LIPG 163/4885CA2 1627/4885 |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | PTGIS, PTGS1, PTGES | LPL 2635/4885LIPG 788/4885CA2 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.